NCT00656305 · REGISTRY CONDITION SEARCH

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: NA
Status at capture: COMPLETED
Registry last update: 2020-02-05

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Responders

→

outcome · POSTED

Number of Participants With a Change in Medication Use

→

outcome · POSTED

Quality of Life (QOL) as Measured by Change in Bodily Pain Inventory (BPI) From Baseline

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion criteria: 1. Men and women age 18 and older 2. Patients who are able and willing to give consent and able to attend all study visits 3. Patients who are suffering from symptoms of bone metastases or multiple myeloma bone lesions and are radiation failure patients: Radiation failure candidates are those who have received radiation without adequate relief from metastatic bone pain as determined by the patient and treating physician, those for whom their treating physician would not prescribe radiation or additional radiation treatments, and those patients who refuse additional radiation therapy, 4. Patients who refuse other accepted available treatments such as surgery or narcotics for pain alleviation. 5. Patient with NRS (0-10 scale) pain score ≥ 4 irrespective of medication 6. Targeted tumor(s) are ExAblate device accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5) 7. Targeted tumor (treated) size up to 55 cm2 in surface area 8. Patient whose targeted (treated) lesion is on bone and the interface between the bone and lesion is deeper than 10-mm from the skin. 9. Targeted (treated) tumor clearly visible by non-contrast MRI, and ExAblate MRgFUS device accessible 10. Able to communicate sensations during the ExAblate treatment 11. Patients on ongoing chemotherapy regimen for at least 1 month at the time of eligibility: \- with same chemotherapy regimen (as documented from patient medical dossier), And \- Worst pain NRS still \>= 4 And \- do NOT plan to initiate a new chemotherapy for pain palliation should be eligible for the study. 12. No radiation therapy to targeted (most painful) lesion in the past two weeks 13. Bisphosphonate intake should remain stable throughout the study duration. 14. Patients will have from 1 to 5 painful lesions and only the most painful lesion will be treated. 15. Patients with persistent distinguishable pain associated with 1 site to be treated (if patient has pain from additional sites, the pain from the additional sites must be evaluated as being less intense by at least 2 points on the NRS compared to the site to be treated). Exclusion Criteria: 1. Patients who either * Need surgical stabilization of the affected bony structure (\>7 fracture risk score, see Section 7.3) OR * Targeted tumor is at an impending fracture site (\>7 on fracture risk score, see Section 7.3). OR \- Patients with surgical stabilization of tumor site with metallic hardware 2. More than 5 painful lesions, or more than 1 requiring immediate localized treatment 3. Targeted (treated) tumor is in the skull 4. Patients on dialysis 5. Patients with life expectancy \< 3-Months 6. patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study. 7. Patients with unstable cardiac status including: * Unstable angina pectoris on medication * Patients with documented myocardial infarction within six months of protocol entry * Congestive heart failure requiring medication (other than diuretic) * Patients on anti-arrhythmic drugs 8. Severe hypertension (diastolic BP \> 100 on medication) 9. Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations (weight \>250 pounds), etc. 10. Patients with an active infection or severe hematological, neurological, or other uncontrolled disease. 11. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease 12. KPS Score \< 60 (See "Definitions" below) 13. Severe cerebrovascular disease (multiple CVA or CVA within 6 months) 14. Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.) 15. Target (treated) tumor is less then 1cm from nerve bundles, bowels or bladder. 16. Are participating or have participated in another clinical trial in the last 30 days 17. Patients initiating a new chemotherapy regime, or radiation (for the targeted most painful lesion) within the last 2 weeks 18. Patients unable to communicate with the investigator and staff. 19. Patients with persistent undistinguishable pain (pain source unidentifiable) 20. Targeted (treated) tumor surface area \>= 55 cm2 21. Patient whose bone-lesion interface is \< 10-mm from the skin 22. Targeted (treated) tumor NOT visible by non-contrast MRI, 23. Targeted (most painful) tumor Not accessible to ExAblate 24. The targeted tumor is less than 2 points more painful compared to other painful lesions on the site specific NRS.
healthy Volunteers: false
maximum Age: 100 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

intervention Names
Device: ExAblate MRfFUS
label
ExAblate Treatment Arm
type
EXPERIMENTAL
intervention Names
Device: ExAblate MRfFUS
Device: Sham
label
ExAblate Sham Arm
type
SHAM_COMPARATOR

interventions

arm Group Labels
ExAblate Sham Arm
ExAblate Treatment Arm
description
MR guided focused ultrasound.
name
ExAblate MRfFUS
other Names
MRgFUS
FUS
Focused Ultrasound
MR guided Focused Ultrasound
type
DEVICE
arm Group Labels
ExAblate Sham Arm
description
sham comparator
name
Sham
type
DEVICE

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: SINGLE
who Masked: PARTICIPANT

primary Purpose

TREATMENT

Enrollment

count: 147
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Using the Numerical Rating Score (NRS) for pain (0 being no pain and 10 being worst imaginable pain), each subject was rated as a Responder or Non-responder. A responder is defined as a subject with a reduction in NRS worst score from baseline of two (2) or more points, and no increase in pain medication use.
measure
Number of Responders
time Frame
3 months post treatment

secondary Outcomes

description
Medication Use change reported from baseline until of study. Medication use is quantified by "morphine equivalent usage" (measured separately from Responder/Non-responder definition for the primary endpoint)
measure
Number of Participants With a Change in Medication Use
time Frame
3 months post treatment
description
The BPI-QOL questionnaire is designed to show the severity and interference of pain in the lives of patients. This is a 7-item questionnaire that asks respondents the extent to which pain interferes with their general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life using a 0-10 numerical rating scale in which 0 represents 'does not interfere' and 10 indicates 'completely interferes'. Responses to the 7 items are averaged to form the pain interference scale score. Lower scores are better, showing less interference in daily activities while higher scores show more interference and hence worse outcomes.
measure
Quality of Life (QOL) as Measured by Change in Bodily Pain Inventory (BPI) From Baseline
time Frame
3 months post treatment

Full study description

brief Summary: A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Source references

references

citation
Bitton RR, Rosenberg J, LeBlang S, Napoli A, Meyer J, Butts Pauly K, Hurwitz M, Ghanouni P. MRI-Guided Focused Ultrasound of Osseous Metastases: Treatment Parameters Associated With Successful Pain Reduction. Invest Radiol. 2021 Mar 1;56(3):141-146. doi: 10.1097/RLI.0000000000000721.
pmid
32858582
type
DERIVED
citation
Hurwitz MD, Ghanouni P, Kanaev SV, Iozeffi D, Gianfelice D, Fennessy FM, Kuten A, Meyer JE, LeBlang SD, Roberts A, Choi J, Larner JM, Napoli A, Turkevich VG, Inbar Y, Tempany CM, Pfeffer RM. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. J Natl Cancer Inst. 2014 Apr 23;106(5):dju082. doi: 10.1093/jnci/dju082.
pmid
24760791
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-3a4bca720dbd5b50a50d
requested nct id
NCT00656305
primary nct id
NCT00656305
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
b8ef0fdb7ea8e211c8738d9f0d6c3871b4a3adcb2a9832d7cbf5d8bbdf79f5d5
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-3a4bca720dbd5b50a50d
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00656305
occurrences
context exact
NCT00656305
end
11
exact text
NCT00656305
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/137/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
94432a2139432b33b055bb9765c240ebaf8519040d95e9f7594f0134f05ee6e8
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice